Current Issue : April-June Volume : 2026 Issue Number : 2 Articles : 5 Articles
MN arrays are highly beneficial for transdermal drug delivery, primarily due to reduced pain and improved compliance. However, complex processing and restricted design freedom limit traditional fabrication. We utilized stereolithography (SLA) 3D printing as a breakthrough method to achieve the one-step production of MN arrays with customized geometries (structure, size, tip angle), enabling tunable release profiles and eliminating cumbersome manufacturing steps. After fabricating conical and grooved MN arrays and validating them in an ex vivo porcine skin model, we confirmed their functionality. Notably, the grooved design provided excellent penetration, requiring only 2.2 N of force for full insertion (at 18.92◦ tip angle), and demonstrated an enhanced drug loading capacity of 4.8 μg released over 2 h. These results underscore the significant potential of 3D-printed, channel-structured MN arrays as a new generation of high-performance transdermal delivery devices....
Cannabidiol (CBD) is a non-psychoactive phyto-cannabinoid with numerous pharmacological potentials. CBD is a lipophilic drug with poor and varied bioavailability due to its low water solubility and extensive first-pass metabolism, and it is highly affected by the presence of food. A self-emulsifying drug delivery system (SEDDS) was developed to improve the aqueous solubility and oral bioavailability of CBD. The formulation strategy involved incorporating excipients that maintain drug solubility under both fasted and fed conditions, while potentially mitigating first-pass metabolism to enhance overall bioavailability and dose proportionality. Caproyl® 90, Tween® 20, and Transcutol® HP were selected as the oil phase, surfactant, and cosolvent, respectively, for formulation preparation and screening. CBD SEDDS formulations containing Caproyl® 90 ≤20% w/w and Tween® 20 above 40% w/w yield particles below 200 nm. CBD SEDDS with Tween® 20 65% w/w or higher showed in vitro release of more than 90%. After in vitro digestion, CTT1, CTT4, and CTT8 remained stable under gastrointestinal conditions and maintained CBD solubility of at least 50%. The most promising formulations, CTT4 and CTT8, were used for in vivo evaluations. Both formulations showed similar in vitro results; however, in vivo, CTT4 demonstrated 2.4-fold higher bioavailability than CTT8. Overall, optimizing the level of inhibitory surfactant appears to be a promising strategy for improving CBD bioavailability....
Background/Objectives: Regenerating critical-sized bone defects is a significant clinical challenge. Autogenous bone grafts are the gold standard but have limitations, including donor site morbidity. As an alternative, this study introduces a novel biocomposite combining an ethyl cyanoacrylate (ECA) polymer with Hancornia speciosa (Hs) latex. The ECA acts as a scaffold and delivery vehicle for the latex, which contains phytochemicals with known angiogenic properties. Methods: We created 5 mm critical-sized calvarial defects in 36 Wistar rats, which were divided into four experimental groups. Bone regeneration was evaluated at 30, 60, and 90 days using micro-computed tomography (micro-CT) for morphometric analysis and hematoxylin and eosin staining for histology. Results: The composite-treated group (Hs+ECA) showed significantly higher bone volume (57.2; IQR: 56.7–61.2) than the control (53.9; IQR: 49.4–56.4) and ECA-only (48.4; IQR: 47.2–59.9) groups at 90 days (p < 0.05). By day 60, the bone volume in the Hs+ECA group was statistically similar (p > 0.05) to that of the autogenous bone group. Histological analysis revealed an organized repair process with neoangiogenesis observed only in the Hs+ECA group, confirming the material’s strong bioactivity. Conclusions: The Hs+ECA composite is a promising biomaterial that acts as an effective delivery system for the bioactive components of the latex. The induced angiogenesis was critical to its regenerative success. This cost-effective material warrants further investigation for clinical applications in regenerative dentistry....
Background: Pelubiprofen (PBF) is a cyclooxygenase-2 inhibitor currently marketed as an oral tablet in South Korea. Oral dosing is limited by gastrointestinal variability, first-pass metabolism, which can reduce therapeutic efficiency and increase adverse effects. Transdermal drug-in-adhesive patches provide a noninvasive alternative that bypasses these limitations and enables controlled delivery through the skin. Methods: The solubility of PBF in ethanol was evaluated, and its adhesive compatibility was tested using acrylicand silicone-based systems. Different drug-loaded formulations were prepared, and their miscibility was assessed. Several permeation enhancers were screened. The physicochemical properties were analyzed. In vitro permeation was studied using rat skin in Franz cells. Accelerated stability was tested at 40 ◦C and 75% relative humidity for three months. Results: PBF reached near saturation at 120 mg/mL in ethanol. Among the adhesives, Duro-Tak® 8076 showed the best compatibility with ethanol and PBF. Drug loading above 15% led to crystallization; 15% was selected as the optimal loading. The addition of 2% oleic acid (OA) significantly increased the permeation flux to 11.31 ± 1.50 μg/cm2/h, showing a 3.6-fold enhancement over the control and enhanced deposition in the stratum corneum and dermis. Based on the physicochemical evaluation, PBF was present in an amorphous state within the adhesive matrix. Stability studies revealed no recrystallization, with the drug content maintained at 97–100%. Permeation remained unchanged during storage. Conclusions: The PD-OA2 patch achieved stable drug incorporation, enhanced skin permeation, and robust stability. These findings support the potential of PBF as a clinically relevant alternative to oral PBF formulations for treating localized inflammation and pain....
Effective management of multidrug-resistant cancers depends on effective, localized drug release and accumulation within the tumor microenvironment. In our work, Pluronic P105 and F127 mixed nanogels (PM) were fabricated through self-assembly to combat multidrug-resistant cancer. The approximate diameter of our prepared PM is 115.7 nm, an optimal size for tumor accumulation through the enhanced permeability and retention (EPR) effect. An in vitro drug release assay indicated that ultrasound could accelerate the drug release rate in doxorubicin-loaded Pluronic nanogels (PM/D). Additionally, the resistance reversion index (RRI) in the ultrasound-treated PM/D group was 4.55 and was two times higher than that in the free PM/D group, which represented better MDR reverse performance. Cell experiments demonstrated that, after 3 min of ultrasound, a greater amount of chemo-drug was released and absorbed by the MDR human breast cell line (MCF-7/ADR), resulting in significant cytotoxicity. Such enhanced therapeutic efficiency could be attributed to the combined effects of the two independent mechanisms: (i) ultrasound-controllable drug release realized effective release within resistant tumors with spatial and temporal precision and (ii) the contained Pluronic in the PM/D inhibited P-gp-mediated efflux activity to overcome MDR in tumors. Collectively, our findings support the feasibility of ultrasound-responsive PM as a drug-delivery platform for resistant cancers....
Loading....